University of Manitoba Researchers Explore Genetic Testing for Mental Health Medications

A team of researchers from the University of Manitoba is launching a study aimed at improving mental health treatment through genetic testing. The initiative seeks to eliminate uncertainty in prescribing medications by offering pharmacogenomic testing to participants, potentially transforming how mental health conditions are treated.

This research will provide free genetic testing for 200 adults who are either starting a new medication or switching from their current treatment. The goal is to tailor mental health medications based on each individual’s unique genetic profile. As explained by Dr. Abdullah Maruf, the lead investigator and assistant professor in the university’s College of Pharmacy, many individuals with mental health conditions often endure a lengthy process of trial and error with various medications. “Sometimes it takes months or years to find a treatment that works with fewer side effects,” he stated.

Pharmacogenomic testing assesses how a person’s genetic makeup influences their response to specific medications. Currently, such testing is privately available in Manitoba, costing approximately $500 out-of-pocket. While some private insurance plans may cover certain tests, there is no provision for public health coverage in any Canadian province. The research team hopes this study will pave the way for broader access to genetic testing within the public health system.

Potential Economic Benefits of Genetic Testing

The implications of this research extend beyond individual patient care. Dr. Jitender Sareen, head of psychiatry at the Max Rady College of Medicine, cited a 2023 study from British Columbia, which suggested that universal access to genetic testing for depression could save the province $1 billion in health care costs over 20 years. This testing could significantly narrow down medication options, reducing the number of potential treatments from as many as 40 to perhaps five or ten.

Dr. Sareen emphasized that the aim of the research is to influence health policy by demonstrating that pharmacogenomic testing is a cost-effective intervention. “We’re trying to continue to make this more available in inpatient and outpatient settings,” he said. By allowing for quicker identification of effective treatments, this testing could help prevent delays in recovery, thereby reducing frustration for patients and potentially decreasing hospitalizations.

Collaboration and Support for the Study

The initiative has garnered financial support, receiving $70,000 from the Health Sciences Centre Foundation and $50,000 from the university’s psychiatry department. Funding is designated for the recruitment of patients through to 2027, but Dr. Maruf expressed hopes that additional funding could allow for an increased number of participants and further investigate the potential of genetic testing to lower hospitalization rates in Manitoba.

To participate, individuals must be referred by a physician, who can submit a referral form to the research team. Eligible patients will be required to complete a survey and provide a saliva sample for analysis.

The importance of this research is underscored by the prevalence of mental health disorders, with over one in four adults in Manitoba experiencing some form of mental illness. Health Minister Uzoma Asagwara acknowledged the initiative, stating that any new additions to the public health system would necessitate thorough evaluation. “We appreciate the efforts of Manitoba researchers and look forward to reviewing the study results once they are available,” Asagwara said.

This groundbreaking research at the University of Manitoba stands to make a significant impact on mental health treatment, offering hope for more personalized, effective medication strategies while potentially reshaping public health policies in Canada.